Repozitorij Univerze v Novi Gorici

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po
* po starem in bolonjskem študiju

Opcije:
  Ponastavi


31 - 40 / 45
Na začetekNa prejšnjo stran12345Na naslednjo stranNa konec
31.
Mass composition of ultra-high energy cosmic rays at the Pierre Auger Observatory
Gašper Kukec Mezek, 2019, doktorska disertacija

Opis: Cosmic rays with energies above 10^18 eV, usually referred to as ultra-high energy cosmic rays (UHECR), have been a mystery from the moment they have been discovered. Although we have now more information on their extragalactic origin, their direct sources still remain hidden due to deviations caused by galactic magnetic fields. Another mystery, apart from their production sites, is their nature. Their mass composition, still uncertain at these energies, would give us a better understanding on their production, acceleration, propagation and capacity to produce extensive air showers in the Earth's atmosphere. Mass composition studies of UHECR try to determine their nature from the difference in development of their extensive air showers. In this work, observational parameters from the hybrid detection system of the Pierre Auger Observatory are used in a multivariate analysis to obtain the mass composition of UHECR. The multivariate analysis (MVA) approach combines a number of mass composition sensitive variables and tries to improve the separation between different UHECR particle masses. Simulated distributions of different primary particles are fitted to measured observable distributions in order to determine individual elemental fractions of the composition. When including observables from the surface detector, we find a discrepancy in the estimated mass composition between a mixed simulation sample and the Pierre Auger data. Our analysis results from the Pierre Auger data are to a great degree independent on hadronic interaction models. Although they differ at higher primary masses, the different models are more consistent, when combining fractions of oxygen and iron. Compared to previously published results, the systematic uncertainty from hadronic interaction models is roughly four times smaller. Our analysis reports a predominantly heavy composition of UHECR, with more than a 50% fraction of oxygen and iron at low energies. The composition is then becoming heavier with increasing energy, with a fraction of oxygen and iron above 80% at the highest energies.
Ključne besede: astroparticle physics, ultra-high energy cosmic rays, extensive air showers, mass composition, Pierre Auger Observatory, machine learning, multivariate analysis
Objavljeno v RUNG: 03.04.2019; Ogledov: 5003; Prenosov: 187
.pdf Celotno besedilo (17,53 MB)

32.
Controlling grape aromatic maturity in the context of global warming
Guillaume Antalick, Katja Suklje, vabljeno predavanje na konferenci brez natisa

Ključne besede: Wine style, grape maturity, berry shrivelling, berry sugar loading, fresh mass, sequential harvest
Objavljeno v RUNG: 19.09.2018; Ogledov: 3201; Prenosov: 0
Gradivo ima več datotek! Več...

33.
34.
35.
Results from the Pierre Auger Observatory
Ivan De Mitri, Andrej Filipčič, Samo Stanič, Darko Veberič, Danilo Zavrtanik, Marko Zavrtanik, 2015, objavljeni znanstveni prispevek na konferenci

Ključne besede: Pierre Auger Observatory, Ultra High Energy Cosmic Rays (UHECR), UHECR energy spectrum, UHECR mass composition
Objavljeno v RUNG: 27.06.2017; Ogledov: 4189; Prenosov: 0
Gradivo ima več datotek! Več...

36.
37.
38.
Development and Validation of a High- Performance Liquid Chromatography– Tandem Mass Spectrometry Method for the Simultaneous Determination of Irinotecan and Its Main Metabolites in Human Plasma and Its Application in a Clinical Pharmacokinetic Study
Bianca Posocco, Elisa Mazzega, Elena Marangon, Giuseppe Toffoli, 2015, izvirni znanstveni članek

Opis: Irinotecan is currently used in several cancer regimens mainly in colorectal cancer (CRC). This drug has a narrow therapeutic range and treatment can lead to side effects, mainly neutropenia and diarrhea, frequently requiring discontinuing or lowering the drug dose. A wide inter-individual variability in irinotecan pharmacokinetic parameters and pharmacodynamics has been reported and associated to patients’ genetic background. In particular, a polymorphism in the UGT1A1 gene (UGT1A1*28) has been linked to an impaired detoxification of SN-38 (irinotecan active metabolite) to SN-38 glucuronide (SN-38G) leading to increased toxicities. Therefore, therapeutic drug monitoring of irinotecan, SN-38 and SN-38G is recommended to personalize therapy. In order to quantify simultaneously irinotecan and its main metabolites in patients’ plasma, we developed and validated a new, sensitive and specific HPLC–MS/MS method applicable to all irinotecan dosages used in clinic. This method required a small plasma volume, addition of camptothecin as internal standard and simple protein precipitation. Chromatographic separation was done on a Gemini C18 column (3 μM, 100 mm x 2.0 mm) using 0.1% acetic acid/bidistilled water and 0.1% acetic acid/acetonitrile as mobile phases. The mass spectrometer worked with electrospray ionization in positive ion mode and selected reaction monitoring. The standard curves were linear (R20.9962) over the concentration ranges (10–10000 ng/mL for irinotecan, 1–500 ng/mL for SN-38 and SN-38G and 1–5000 ng/mL for APC) and had good back-calculated accuracy and precision. The intra- and inter-day precision and accuracy, determined on three quality control levels for all the analytes, were always <12.3% and between 89.4% and 113.0%, respectively. Moreover, we evaluated this bioanalytical method by re-analysis of incurred samples as an additional measure of assay reproducibility. This method wassuccessfully applied to a pharmacokinetic study in metastatic CRC patients enrolled in a genotype-guided phase Ib study of irinotecan administered in combination with 5-fluorouracil/ leucovorin and bevacizumab.
Ključne besede: Pharmacokinetic, pharmacodynamics, phase I clinical study, colorectal cancer, Mass spectrometry, pharmacogenetics
Objavljeno v RUNG: 21.03.2017; Ogledov: 4624; Prenosov: 0
Gradivo ima več datotek! Več...

39.
40.
Iskanje izvedeno v 0.06 sek.
Na vrh